CSL snags a preclinical stem cell therapy in $416M Calimmune … – Endpoints News
Endpoints News |
CSL snags a preclinical stem cell therapy in $416M Calimmune …
Endpoints News CSL Behring has bagged the stem cell gene therapy player Calimmune for $91 million and another $325 million in milestones for the years-long clinical journey … CSL Behring buys Calimmune for early stem cell, gene therapy boost $91M Deal: CSL Acquires California Stem Cell Gene Therapy Developer CSL Behring to Acquire Biotech Company Calimmune and its … |
